| Abstract |
Objective This experiment will focus on the implementation of treatment for patients with chronic bronchitis, focusing on the analysis of moxifloxacin combined with cephalosporin antimicrobial therapy, to help patients achieve the ideal treatment outcome and optimize the treatment plan. Methods A total of 80 patients with chronic bronchitis were selected as the object, and the samples were collected from patients before June 2021 to June 2022. According to the time, they were divided into two comparison groups. The control group was treated with cephalosporin antibiotics, and the observation group was treated with moxifloxacin combined with cepha- losporin antibiotics. Results According to the data, the time of symptom relief (cough, dyspnea, fever, pulmonary moist rales) in the observation group was shorter than that in the control group, with statistical significance (P<0.05). At the same time, in the improvement of PaO2, PaCO2 and FeNO levels, the blood gas index levels of the observation group were better than those of the control group, and the differences were significant (P<0.05). In addition, in the comparison of the levels of inflammatory factors in patients, the data of each item in the observation group were better than those in the control group, and the comparison difference was large. Finally, the total efficacy of the observation group was 95.0% higher than that of the control group (77.5%), and the difference was significant (P<0.05). Conclusion The use of moxifloxacin combined with cephalosporin in the treatment of chronic bronchitis patients is helpful to improve the blood gas status of patients, is conducive to the disease outcome, achieve a good treatment effect, worthy of promotion.
|